Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1

Interventions

Cyclophosphamide 26fludarabine 18Dexamethasone 17pembrolizumab 12Rituximab 11Etoposide 10venetoclax 9pomalidomide 9Gemcitabine 9fludarabine phosphate 7daratumumab 7Lenalidomide 7Bortezomib 7carfilzomib 6obinutuzumab 5glofitamab 5Vincristine 5Temozolomide 5Prednisone 5Nivolumab 5Immunotherapy, Adoptive 5Cisplatin 5Calcium Dobesilate 5selinexor 4cemiplimab 4Doxorubicin 4Cytarabine 4Carboplatin 4zanubrutinib 3ruxolitinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × INCB057643 × 90 days × Clear all
NCT04279847 2026-04-01

LIMBER

Incyte Corporation

Phase 1 Active not recruiting
140 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡